{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:00:45Z","timestamp":1789513245708,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Antitumor medications such as Avastin, Berubicin, and Temozolomide have fundamentally transformed the treatment landscape for gliomas by exhibiting potent pharmacological effects on both high-grade and low-grade gliomas. This study aims to determine which anti-glioma medication presents the lowest risk for personalized use in clinical patients by assessing the adverse drug reactions (ADRs) associated with these medications as reported in the World Health Organization (WHO) VigiAcess database, and by comparing the characteristics of adverse responses among the three drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This investigation employs a retrospective descriptive analysis method. We compiled ADR reports for three commercially available anti-glioma medications from WHO-VigiAccess, gathering data on the disease systems and symptoms associated with ADRs, as well as the age, gender, and geographic characteristics of the patients represented in the reports. To provide a reference for clinical treatment, we analyzed the similarities and differences in the adverse reactions of the three medications by calculating the proportion of adverse reactions recorded for each drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 132,471 adverse events (AEs) associated with three anti-glioma drugs were reported in VigiAccess. The analysis revealed that the ten most frequently reported AEs included bone marrow suppression, myalgia, leukopenia, thrombocytopenia, nausea, vomiting, death, rhabdomyolysis, disease progression, and a decrease in neutrophil count. The five most common categories of AEs related to anti-glioma drugs were blood and lymphatic system diseases (20,233 cases, 15.2%), general disorders and administration site conditions (26,973 cases, 20.3%), gastrointestinal dysfunction (22,061 cases, 16.7%), necessitating further investigations (18,285 cases, 13.8%), and musculoskeletal and connective tissue diseases (30,695 cases, 23.1%). Notably, the adverse events associated with Avastin were more pronounced in the category of musculoskeletal and connective tissue diseases compared to the other two drugs. Furthermore, Berubicin exhibited a particularly high proportion of blood and lymphatic system disease AEs, reaching 45.6%, which was significantly greater than those observed for the other two drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is limited correlation between antineoplastic medications and ADRs. Current comparative observational studies indicate that these inhibitors are associated with both common and specific adverse effects documented in the ADR reports submitted to the World Health Organization (WHO).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1485067","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T04:47:16Z","timestamp":1729745236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess"],"prefix":"10.3389","volume":"15","author":[{"given":"Huadong","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","article-title":"Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase\u00ae","volume":"39","author":"Ampadu","year":"2016","journal-title":"Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5853\/jos.2016.00864","article-title":"Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update","volume":"19","author":"An","year":"2017","journal-title":"J. Stroke"},{"key":"B4","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3346\/jkms.2014.29.7.980","article-title":"Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea","volume":"29","author":"Bae","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"B3","first-page":"121","article-title":"Disparities in premature deaths from heart disease-50 States and the District of Columbia, 2001","volume":"53","year":"2004","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14740338.2019.1630063","article-title":"Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseases","volume":"18","author":"Chen","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13311-017-0519-x","article-title":"Glioma subclassifications and their clinical significance","volume":"14","author":"Chen","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","article-title":"Role of anthracyclines in the era of targeted therapy","volume":"7","author":"Cort\u00e9s-Funes","year":"2007","journal-title":"Cardiovasc Toxicol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"102234","DOI":"10.1016\/j.canep.2022.102234","article-title":"Trends in brain cancers (glioma) in New Zealand from 1995 to 2020, with reference to mobile phone use","volume":"80","author":"Elwood","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3390\/pharmaceutics14112328","article-title":"Real-world safety profile of biologics used in rheumatology: a six-year observational pharmacovigilance study in the calabria region","volume":"14","author":"Gagliardi","year":"2022","journal-title":"Pharmaceutics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1188\/09.CJON.54-64","article-title":"Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes","volume":"13","author":"Hawkins","year":"2009","journal-title":"Clin. J. Oncol. Nurs."},{"key":"B15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1073\/pnas.1014480108","article-title":"Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma","volume":"108","author":"Keunen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3332\/ecancer.2021.1166","article-title":"Safety and efficacy of bevacizumab biosimilar in recurrent\/progressive glioblastoma","volume":"15","author":"Kumar","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"B18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1126\/science.abn7570","article-title":"Mechanism-based design of agents that selectively target drug-resistant glioma","volume":"377","author":"Lin","year":"2022","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s0921-8777(01)00105-7","article-title":"Repair of O6-methylguanine is not affected by thymine base pairing and the presence of MMR proteins","volume":"487","author":"Lips","year":"2001","journal-title":"Mutat. Research\/DNA Repair"},{"key":"B21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11060-011-0748-5","article-title":"Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts","volume":"107","author":"Lorgis","year":"2012","journal-title":"J. Neurooncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/cmdc.202000131","article-title":"Antitumour anthracyclines: progress and perspectives","volume":"15","author":"Martins-Teixeira","year":"2020","journal-title":"ChemMedChem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","article-title":"Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine","volume":"332","author":"McDowell","year":"2006","journal-title":"Bmj"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.12968\/bjon.2011.20.Sup10.S7","article-title":"Effectively managing chemotherapy-induced nausea and vomiting","volume":"20","author":"Middleton","year":"2011","journal-title":"Br. J. Nurs."},{"key":"B26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J. Neurooncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/jjco\/hys121","article-title":"Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma","volume":"42","author":"Nagane","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10014-010-0007-z","article-title":"Angiogenesis and invasion in glioma","volume":"28","author":"Onishi","year":"2011","journal-title":"Brain Tumor Pathol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1200\/JOP.2012.000560","article-title":"Economics of malignant gliomas: a critical review","volume":"11","author":"Raizer","year":"2015","journal-title":"J. Oncol. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2147\/DDDT.S224857","article-title":"Optimal approach and strategies to strengthen pharmacovigilance in sub-saharan Africa: a cohort study of patients treated with first-line artemisinin-based combination therapies in the nanoro health and demographic surveillance system, Burkina Faso","volume":"14","author":"Rouamba","year":"2020","journal-title":"Drug Des. Devel Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4314\/gmj.v48i4.4","article-title":"Adverse drug reaction reporting by doctors in a developing country: a case study from Ghana","volume":"48","author":"Sabblah","year":"2014","journal-title":"Ghana Med. J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1161\/CIRCULATIONAHA.107.726562","article-title":"Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry","volume":"117","author":"Shaw","year":"2008","journal-title":"Circulation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00228-012-1219-4","article-title":"Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009","volume":"68","author":"Srba","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/biomedicines7030069","article-title":"Temozolomide and other alkylating agents in glioblastoma therapy","volume":"7","author":"Strobel","year":"2019","journal-title":"Biomedicines"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1248\/bpb.b22-00496","article-title":"Central nervous system ischemia associated with bevacizumab: an analysis of the Japanese adverse drug event report database","volume":"45","author":"Sugimoto","year":"2022","journal-title":"Biol. Pharm. Bull."},{"key":"B37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2020.00315","article-title":"Intravitreal anti-VEGF drugs and signals of dementia and Parkinson-like events: analysis of the VigiBase database of spontaneous reports","volume":"11","author":"Sultana","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2019","journal-title":"Med. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ahj.2010.06.014","article-title":"Racial differences in long-term survival among patients with coronary artery disease","volume":"160","author":"Thomas","year":"2010","journal-title":"Am. Heart J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","article-title":"Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions","volume":"26","author":"van Puijenbroek","year":"2003","journal-title":"Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11910-014-0443-y","article-title":"Resistance to antiangiogenic therapy","volume":"14","author":"Weathers","year":"2014","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"44015","DOI":"10.18632\/oncotarget.17054","article-title":"Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1485067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T04:47:18Z","timestamp":1729745238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1485067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":42,"alternative-id":["10.3389\/fphar.2024.1485067"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1485067","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"article-number":"1485067"}}